Inhibitors of p38

A compound having the formula:

• 23
• or pharmaceutically acceptable salts thereof, wherein:
• each of Q1 and Q2 are independently selected from 5-6 membered aromatic carbocyclic or heterocyclic ring systems, or 8-10 membered bicyclic ring systems consisting of aromatic carbocyclic rings, aromatic heterocyclic rings or a combination of an aromatic carbocyclic ring and an aromatic heterocyclic ring;
• wherein:
• Q1 is substituted with 1 to 4 substituents, independently selected from halo;
• C1-C3 alkyl optionally substituted with NR′2, OR′, CO2R′ or CONR′2;
• O—(C1-C3)-alkyl optionally substituted with NR′2, OR′, CO2R′ or CONR′2;
• NR′2;
• OCF3;
• CF3;
• NO2;
• CO2R′;
• CONR′;
• SR′;
• S(O2)N(R′)2;
• SCF3;
• CN;
• N(R′)C(O)R4;
• N(R′)C(O)OR4;
• N(R′)C(O)C(O)R4;
• N(R′)S(O2)R4;
• N(R′)R4;
• N(R4)2;
• OR4;
• OC(O)R4;
• OP(O)3H2;
• or N═C—N(R′)2;
• Q2 is optionally substituted with up to 4 substituents, independently selected from halo;
• C1-C3 straight or branched alkyl optionally substituted with NR′2, OR′, CO2R′, S(O2)N(R′)2, N═C—N(R′)2, R3, or CONR′2;
• O—(C1-C3)-alkyl optionally substituted with NR′2, OR′, CO2R′, S(O2)N(R′)2, N═C—N(R′)2, R3, or CONR′2;
• NR′2;
• OCF3;
• CF3;
• NO2;
• CO2R′;
• CONR′;
• R3;
• OR3;
• NR3;
• SR3;
• C(O)R3;
• C(O)N(R′)R3;
• C(O)OR3;
• SR′;
• S(O2)N(R′)2;
• SCF3;
• N═C—N(R′)2;
• or CN;
• R′ is selected from hydrogen, (C1-C3)-alkyl;
• (C2-C3)-alkenyl or alkynyl;
• phenyl or phenyl substituted with 1 to 3 substituents independently selected from halo, methoxy, cyano, nitro, amino, hydroxy, methyl or ethyl;
• R3 is selected from a 5-6 membered aromatic carbocyclic or heterocyclic ring system;
• and
• R4 is (C1-C4)-alkyl optionally substituted with N(R′)2, OR′, CO2R′, CON(R′)2, or SO2N(R2)2;
• or a 5-6 membered carbocyclic or heterocyclic ring system optionally substituted with N(R′)2, OR′, CO2R′, CON(R′)2, or SO2N(R2)2;
• X, if present, is selected from —S—, —O—, —S(O2)—, —S(O)—, —S(O2)—N(R2)—, —N(R2)—S(O2)—, —N(R2)—C(O)O—, —O—C(O)—N(R2), —C(O)—, —C(O)O—, —O—C(O)—, —C(O)—N(R2)—, —N(R2)—C(O)—, —N(R2)—, —C(R2)2—, —C(OR2)2—;
• each R is independently selected from hydrogen, —R2, —N(R2)2, —OR2, SR2, —C(O)—N(R2)2, —S(O2)—N(R2)2, or —C(O)—OR2, wherein two adjacent R are optionally bound to one another and, together with each. Y to which they are respectively bound, form a 4-8 membered carbocyclic or heterocyclic ring;
• R2 is selected from hydrogen, (C1-C3)-alkyl, or (C1-C3)-alkenyl;
• each optionally substituted with —N(R′)2, —OR′, SR′, —C(O)—N(R′)2, —S(O2)—N(R′)2, —C(O)—OR′, or R3;
• Y is selected from N or C;
• Z, if present, is selected from O, N or NH;
• A, if present, is selected from N or CR′;
• n is 0 or 1;
• and
• R1 is selected from hydrogen, (C1-C3)-alkyl, OH, or O—(C1-C3)-alkyl.